Incannex Healthcare study results point to IHL-675A as a treatment option for rheumatoid arthritis

Retrieved on: 2021-03-15 23:26:15

Tags for this article:

Medical specialties

Medicine

Click the tags to see associated articles and topics

Incannex Healthcare study results point to IHL-675A as a treatment option for rheumatoid arthritis. View article details on HISWAI: https://smallcaps.com.au/incannex-healthcare-study-results-ihl-675a-treatment-rheumatoid-arthritis/

Excerpt

The study model assessed the anti-inflammatory capabilities of IHL-675A – which combines cannabidiol (CBD) and hydroxychloroquine (HCQ) – and ...

Article found on: smallcaps.com.au

View Original Article